Reset filter
Keywords
Hematology ×
Neurology ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

5 Search results.

Relevance Rating New first Old first

Lamotrigine as add-on therapy in patients with a clinical diagnosis of a Lennox-Gastaut syndrome (105-123) - Visit 4; Visit 7/ Final Assessment - Haematology/ Clinical Chemistry; AED Plasma Concentration

- 9/23/19 - 1 form, 4 itemgroups, 18 items, 1 language
Itemgroups: Administrative,Haematology,Clinical Chemistry,Plasma Concentrations of AEDs
Study ID: 105-123 Clinical Study ID: 105-123 Study Title: Lamotrigine as add-on therapy in patients with clinical diagnosis of a Lennox-Gastaut syndrome (severe generalised epilepsy of childhood onset.) A multicentre, double-blind, placebo controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Lamotrigine Study Indication: Seizures

Lamotrigine as add-on therapy in patients with a clinical diagnosis of a Lennox-Gastaut syndrome (105-123) - Visit 1 / Screen - Haematology/ Clinical Chemistry; AED Plasma Concentration

- 9/12/19 - 1 form, 4 itemgroups, 18 items, 1 language
Itemgroups: Administrative,Haematology,Clinical Chemistry,Plasma Concentrations of AEDs
Study ID: 105-123 Clinical Study ID: 105-123 Study Title: Lamotrigine as add-on therapy in patients with clinical diagnosis of a Lennox-Gastaut syndrome (severe generalised epilepsy of childhood onset.) A multicentre, double-blind, placebo controlled parallel group study Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Lamotrigine Study Indication: Seizures

Bioequivalence of Sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose; 102146 - Unscheduled

- 7/3/19 - 1 form, 4 itemgroups, 29 items, 1 language
Itemgroups: Administrative documentation,Laboratory Procedures, Hematology finding,Laboratory Procedures, Chemistry, Clinical,Laboratory Procedures, Urinalysis, Abnormality
Study ID: 102146 Clinical Study ID: SUM102146 Study Title: An open-label, randomized, three-period crossover study to demonstrate the bioequivalence of sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose after dose-normalization, and to assess the relative bioavailability of 4 mg sumatriptan injected using the STATdose device compared to 4 mg sumatriptan injected manually Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran Study Indication: Migraine Disorders

Bioequivalence of Sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose; 102146 - Unscheduled

- 6/24/19 - 1 form, 4 itemgroups, 29 items, 1 language
Itemgroups: Administrative documentation,Laboratory Procedures, Abnormality, Hematology finding,Laboratory Procedures, Chemistry, Clinical, Abnormality,Laboratory Procedures, Urinalysis, Abnormality
Study ID: 102146 Clinical Study ID: SUM102146 Study Title: An open-label, randomized, three-period crossover study to demonstrate the bioequivalence of sumatriptan 4 mg STATdose to IMITREX™ 6 mg STATdose after dose-normalization, and to assess the relative bioavailability of 4 mg sumatriptan injected using the STATdose device compared to 4 mg sumatriptan injected manually Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: sumatriptan Trade Name: Imitrex ,Imiject ,Imigran Study Indication: Migraine Disorders

visit 1 & 4 laboratory evaluation hematology starting dose of ropinirole Parkinson's Disease 101468/166

- 9/4/17 - 1 form, 17 itemgroups, 47 items, 1 language
Itemgroups: administrative data,number of visit,hematology,hemoglobin,packed cell volume,red blood cells,mean corpuscular hemoglobin,mean corpuscular hemoglobin concentration,platelets,white blood cells,segmented neutrophils,neutrophil band cells,lymphocytes,monocytes,eosinophils,basophils,other aspect
Study ID: 101468/166 Clinical Study ID: SKF-101468/166 Study Title: A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 2 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip Study Indication: Parkinson Disease

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial